Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required)

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) intends to accelerate development, innovation and establishment of adoptive cellular therapy clinical trials for treatment of pediatric patients (18 years or younger) with solid tumors. Specifically, UG3 phase of the awards will support preclinical, translational and IND-enabling studies that lay groundwork for UH3 early stage clinical trials testing adoptive immune cell therapies in pediatric patients with solid tumors. This FOA is published in parallel with RFA-CA-22-028 and RFA-CA-22-030 with an aim to develop treatments for adult patients with solid tumors and to establish a coordinating center respectively. The awards funded through these three FOAs will collectively comprise the Cancer Adoptive Cellular Therapy (Can-ACT) Network.